Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry Raftopoulos

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 19, 2007
Diagnosis and management of hyponatremia in cancer patientsHarry Raftopoulos
Hematology/Oncology Clinics of North America|April 19, 2005
Supportive care in lung cancerMichelle Boyar, Harry Raftopoulos
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
Antiemetic studies on the NK1 receptor antagonist aprepitantJohn P Stoutenburg, Harry Raftopoulos
Journal of Oncology Practice|February 17, 2018
Progress in the Control of Chemotherapy-Induced Emesis: New Agents and New StudiesRichard J Gralla, Harry Raftopoulos
Future Oncology (London, England)|August 21, 2015
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteriaHarry Raftopoulos, Ralph Boccia, William Cooper, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 3, 2014
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trialHarry Raftopoulos, William Cooper, Erin O'Boyle, et al.
Cancer Cytopathology|April 12, 2014
Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publicationOana C Rafael, Mohamed Aziz, Harry Raftopoulos, et al.
Lung Cancer (Amsterdam, Netherlands)|June 21, 2008
Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trialsEmilio Bria, Richard J Gralla, Harry Raftopoulos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2002
Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimenM Brigid Bradley, Rose M Sattler, Harry Raftopoulos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 12, 2018
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR MutationJames Chih-Hsin Yang, Shirish M Gadgeel, Lecia VanDam Sequist, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 19, 2007
Diagnosis and management of hyponatremia in cancer patientsHarry Raftopoulos
Hematology/Oncology Clinics of North America|April 19, 2005
Supportive care in lung cancerMichelle Boyar, Harry Raftopoulos
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
Antiemetic studies on the NK1 receptor antagonist aprepitantJohn P Stoutenburg, Harry Raftopoulos
Journal of Oncology Practice|February 17, 2018
Progress in the Control of Chemotherapy-Induced Emesis: New Agents and New StudiesRichard J Gralla, Harry Raftopoulos
Future Oncology (London, England)|August 21, 2015
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteriaHarry Raftopoulos, Ralph Boccia, William Cooper, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 3, 2014
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trialHarry Raftopoulos, William Cooper, Erin O'Boyle, et al.
Cancer Cytopathology|April 12, 2014
Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publicationOana C Rafael, Mohamed Aziz, Harry Raftopoulos, et al.
Lung Cancer (Amsterdam, Netherlands)|June 21, 2008
Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trialsEmilio Bria, Richard J Gralla, Harry Raftopoulos, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2002
Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimenM Brigid Bradley, Rose M Sattler, Harry Raftopoulos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 12, 2018
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR MutationJames Chih-Hsin Yang, Shirish M Gadgeel, Lecia VanDam Sequist, et al.
Pageof 2